Status:
COMPLETED
Impact of EPA and DHA Supplementation on Plasma Biomarkers of Inflammation (n3)
Lead Sponsor:
Laval University
Collaborating Sponsors:
Canadian Institutes of Health Research (CIHR)
Conditions:
Cardiovascular Disease, Inflammation
Eligibility:
All Genders
18-70 years
Phase:
NA
Brief Summary
Subclinical inflammation is now indisputably recognized as a key etiological factor in the development of atherosclerosis and subsequent cardiovascular disease. Obesity and related dysmetabolic states...
Detailed Description
The proposed study will be undertaken according to a double-blind randomized placebo controlled cross-over design with 3 treatment phases: 1- high DHA, 2- High EPA, 3- Control. Each treatment phase wi...
Eligibility Criteria
Inclusion
- Men and women aged between 18 and 70 years with abdominal obesity as defined by the International Diabetes Federation criteria and a measure of plasma CRP \>1 mg/L
- Stable body weight for at least 3 months prior to randomization.
- Pre-menopausal women with regular menstrual cycle (25-35 days)
Exclusion
- Plasma CRP \> 10 mg/L at screening
- Extreme dyslipidemias such as familial hypercholesterolemia
- Previous history of cardiovascular disease (coronary heart disease, cerebrovascular disease or peripheral arterial disease)
- Subjects taking medications known to affect inflammation (e.g. steroids, binging alcohol)
- Subjects taking LCn-3PUFA supplements within 2 months of study onset.
Key Trial Info
Start Date :
March 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2017
Estimated Enrollment :
170 Patients enrolled
Trial Details
Trial ID
NCT01810003
Start Date
March 1 2013
End Date
December 1 2017
Last Update
February 22 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Institute of Nutrition and Functional Foods (INAF), Laval University
Québec, Quebec, Canada, G1V 0A6